Scientific instruments company Waters Corporation (NYSE: WAT) reported Q3 2026 results topping the market’s revenue expectations, with sales up 121% year on year to $1.77 billion. Guidance for next quarter’s revenue was better than expected at $1.81 billion at the midpoint, 1.1% above analysts’ estimates. Its non-GAAP profit of $4.10 per share was 2.6% above analysts’ consensus estimates.

Is now the time to buy WAT? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Waters Corporation’s third quarter saw a positive market reaction, driven by robust growth across its divisions and outperformance versus Wall Street expectations. Management highlighted momentum from both its legacy and acquired businesses, emphasizing double-digit organic revenue growth, successful integration actions, and rising demand in key areas such as pharmaceutical, semiconductor, and data center applications. CEO Udit Batra pointed to the return to growth in China and strong adoption of new instruments, stating, “Growth was strong in every region, led by over 20% growth in China, mid-teens in India, high single digits in the U.S., and mid-single digits in Europe.”

Looking ahead, Waters’ guidance is underpinned by continued product launches, accelerating AI-driven workflows, and anticipated benefits from ongoing cost synergies and operational initiatives. Management expects further momentum from new digital features on the Empower platform, expanded partnerships in diagnostics, and increased demand from AI-enabled laboratories. CFO Amol Chaubal noted, “Volume leverage and further cost synergy realization offer upside potential net of reinvestment,” while Batra emphasized that new growth vectors—including pharma reshoring and semiconductor testing—are expected to build throughout the coming year.

Key insights from management’s remarks

Management attributed the quarter’s results to accelerating product adoption, successful integration of acquired businesses, and increased demand in end markets, particularly pharmaceuticals and China.

• Pharma and Biotech Demand: Waters saw double-digit growth in its pharma segment, with broad demand from pharmaceutical, generics, contract research organizations, and biotech customers. Management cited instrument replacement cycles and expansion into new drug development workflows as drivers.
• China Growth Resurgence: After several quarters of decline, both the legacy and acquired businesses returned to growth in China, aided by local manufacturing and improved execution. Management reported over 20% revenue growth in the region, noting that China is now accretive to overall company growth.
• AI Integration and Empower Platform: The company accelerated the rollout of AI-powered features on its Empower software, including anomaly detection and peak integration, enabling customers to improve productivity and data accuracy. These digital upgrades are supporting the transition to subscription models and increasing user engagement.
• New Product Launches: The launch of the Xevo MRT P10 mass spectrometer and FACSDiscover A7 flow cytometer contributed to instrument growth, with strong early customer traction. Waters is positioning these products to capture opportunities in omics research and clinical diagnostics.
• Acquisition of MOBILion Systems: Waters announced the acquisition of MOBILion Systems, bringing high-resolution ion mobility separation technology into its portfolio. This move is expected to enhance Waters’ capabilities in proteomics and large molecule analysis, expanding its addressable market and supporting future product development.

Drivers of future performance

Waters anticipates continued growth from product innovation, AI-driven laboratory demand, and ongoing cost and revenue synergy capture.

• AI-Driven Experimental Volume: Management expects further acceleration in demand as pharmaceutical and biotech laboratories increasingly utilize AI to design and execute experiments, driving higher instrument usage and consumable sales. The launch of Waters AI Link and continued adoption of Empower AI features position the company to benefit from this trend.
• New Partnerships and Diagnostics Expansion: Recent commercial agreements with LabCorp and Quest Diagnostics for the Onclarity HPV self-collection kit are set to generate incremental revenue as these diagnostics gain traction in the U.S. market. Management views this as an entry point for expanding its clinical menu and strengthening its diagnostics business.
• Operational Efficiency and Margin Expansion: The company is leveraging AI and restructuring initiatives to achieve cost savings ahead of schedule, with an expected operating margin improvement in the coming year. However, management noted that investments in high-growth programs and integration costs may partially offset these gains, requiring disciplined execution to meet margin targets.

Catalysts in upcoming quarters

Looking forward, the StockStory team will track (1) the adoption and monetization of new Empower AI features and premium subscription tiers, (2) the scaling of newly launched instruments like Xevo MRT P10 and FACSDiscover A7, and (3) progress in China’s return to sustainable growth following localization initiatives and DRG policy shifts. We will also monitor integration progress of the MOBILion acquisition and early revenue from new diagnostic partnerships.

Waters Corporation currently trades at $459.76, up from $449.32 just before the earnings. Is there an opportunity in the stock? Find out in our full research report (it’s free).

Our favorite stocks right now

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.